London, United Kingdom | 16 November 2026
ViiV Healthcare, a global specialist HIV pharmaceutical company majority-owned by GSK, with Shionogi as a shareholder, has announced that its HIV medicines Tivicay (dolutegravir) and Dovato (dolutegravir/lamivudine) have received positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The recommendations support expanding the medicines’ use to younger children living with HIV, marking an important development in paediatric HIV treatment across the European Union (EU). The proposed changes aim to address existing treatment gaps by providing age-appropriate antiretroviral therapy options for infants and young children who require effective and long-term HIV management. If the recommendations receive final approval from the European Commission, the expanded indications could improve access to specialised HIV treatment for eligible paediatric patients across Europe.
CHMP Recommends Expanded Use of Tivicay and Dovato
The CHMP has recommended extending the existing indication for Tivicay dispersible tablets, containing dolutegravir, to include eligible term neonates from birth weighing at least 2 kg. The medicine is intended to be administered in combination with other antiretroviral medicines for the treatment of HIV infection. Under the proposed expanded indication, dolutegravir could become the first second-generation integrase strand transfer inhibitor (INSTI) available in the EU for eligible newborns from birth. The recommendation represents an important development because younger infants require carefully selected treatment options that account for their age, body weight, drug exposure and safety requirements.
The committee has also recommended expanding the use of Dovato, a fixed-dose combination of dolutegravir and lamivudine. The proposed extension includes a new 5 mg/30 mg dispersible tablet formulation for children aged at least three months and weighing from 6 kg to less than 25 kg. Additionally, the existing 50 mg/300 mg film-coated tablet indication is recommended for extension to children weighing at least 20 kg. Dovato combines two antiretroviral agents into a single-tablet, two-drug regimen, potentially reducing treatment complexity for eligible younger patients. Both recommendations include restrictions for patients with no known or suspected resistance to the integrase inhibitor class or lamivudine.
Clinical Evidence Supports Paediatric Treatment Expansion
The positive CHMP opinions were supported by clinical and pharmacokinetic evidence evaluating the suitability of dolutegravir-based treatments in younger populations. For Tivicay, the application included data from IMPAACT 2023, a study sponsored by the Division of AIDS and funded by the National Institutes of Health (NIH). Pharmacokinetic modelling incorporating additional paediatric data demonstrated that dolutegravir could achieve therapeutic drug concentrations in term neonates. The assessment also reported no new safety findings compared with those observed in older paediatric populations.
EU Regulatory Decision Expected in Q1 2027
The recommendations represent an important regulatory milestone for ViiV Healthcare’s paediatric HIV treatment portfolio. However, a positive CHMP opinion does not itself constitute final European marketing authorisation. The European Commission decisions for both applications are expected in the first quarter of 2027. Following the final regulatory decisions, updated product information and prescribing recommendations will be made available for healthcare professionals.
Separately, ViiV Healthcare has also submitted a paediatric New Drug Application for dolutegravir/lamivudine in the United States, which remains under review by the US Food and Drug Administration (FDA), with a decision expected in Q1 2027. These parallel regulatory developments demonstrate the continuing focus on expanding access to age-appropriate HIV medicines across major pharmaceutical markets.
Source: ViiV Healthcare press release



